Currently, the potential diagnosis of CLN2 disease is initially based on clinical findings (i.e., retinopathy, motor abnormalities, dementia and/or epilepsy), followed by CLN2 gene sequencing and assessment of TPP1 enzymatic activity to confirm the diagnosis8. The gene discussed is TPP1; the disease is epilepsy.